Your AI-Trained Oncology Knowledge Connection!
Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.
January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.
January 19, 2021 - The FDA’s Center for Devices and Radiological Health has granted premarket approval to diagnostic breast cancer imaging technology developed by Seno Medical Instruments to assist in the differentiation between benign and malignant breast lesions in patients.
January 19, 2021 — The FDA has granted priority review to the biologics license application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.
As oncologists, we are here to help patients and their families as much as we can. That is why we went into cancer medicine. It is what we do every day. Until the coronavirus disease 2019 pandemic knocked on our doors.
Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.
January 18, 2021 — The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer.
Tony S.K. Mok, MD's, early research tackled a grab bag of topics, including pancreatic, colon, and lung cancers, as he tried to catch up with his colleagues.
Despite the availability of next-generation PET imaging modalities that can detect metastasis earlier, apalutamide, enzalutamide, and darolutamide remain the standard of care for patients with nonmetastatic castration-resistant prostate cancer who have a prostate-specific antigen doubling time of less than 10 months.
Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.
Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.
January 18, 2021 - The phase 2 TAMARIN study exploring the activity of tamoxifen on driver variant allele frequency in patients with stable myeloproliferative neoplasms met its primary end point.
Before New Year’s Day, millions of Americans had received the coronavirus disease 2019 vaccine, including frontline physicians and health care providers and nursing home patients, our most vulnerable citizens.
January 17, 2021 - Pembrolizumab demonstrated maintained numerical improvements in overall survival and progression-free survival compared with placebo in patients with previously treated advanced hepatocellular carcinoma.
January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
January 17, 2021 - Infigratinib was found to be associated with encouraging clinical activity with a manageable safety profile in patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.
January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.
January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.
Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.
January 16, 2021 - Lenvatinib monotherapy was found to be effective in patients with unresectable hepatocellular carcinoma in the United States.
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.
January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.
January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.
January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.
The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers
